Cuba has a drug against Alzheimer

Cuba has a drug against Alzheimer

HAVANA, Oct 20  (PL) The Cuban Center for State Control of Medicines, Equipment and Medical Devices is evaluating for its registration the drug called NeuroEpo, an innovative product against Alzheimer’s disease.

Scientists from Cuba demonstrated its safety after long years of pharmaceutical, toxicological, efficacy studies in animals and diseases, and the clinical trial was carried out from 2017 until the end of 2020.

The project – carried out by the Center for Molecular Immunology (CIM), the Center for Research and Development of Medicines and other institutions – consisted of the development of a novel formulation of recombinant human erythropoietin (NeuroEpo), with characteristics similar to that produced by the brain.

The director of Clinical Investigations of the CIM, Tania Crombet, explained that it is a drug for nasal application, very comfortable and easy to use by those who care for the patient.

She highlighted that between 2017 and 2020 the different phases of clinical trials were carried out with NeuroEpo for the treatment of Alzheimer’s, the results of which showed safety and efficacy, with improvements in the rates of cognitive decline, Crombet told the Granma newspaper.

The drug – said the Doctor of Science – has a tendency to stop the progression of the disease in the mild and moderate stages.

According to the medical literature, Alzheimer’s is a progressive mental illness characterized by a degeneration of nerve cells in the brain and a decrease in brain mass; the basic manifestations are memory loss, spatial and temporal disorientation, and intellectual and personal impairment.